---
document_datetime: 2025-12-12 11:02:48
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/libmyris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: libmyris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.4632879
conversion_datetime: 2025-12-19 22:23:00.408399
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Libmyris

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                      |
|----------------------|--------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------|
| Variation type II /  | B.II.d.1 Change in the specification | 11/12/2025                          |                                             | PL                               | The Instructions for Use of the PL have been |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000301918                     | parameters and/or limits of the finished product - B.II.d.1.e Change outside the approved specifications limits range - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     |                                  | updated to change the delivery time from '≤10 seconds' to '≤15 seconds' for the finished product presentations 80 mg solution for injection in pre- filled pen.   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000295642 | This was an application for a group of variations. B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.e.3 Change in test procedure for the immediate packaging of the finished product - B.II.e.3.a Minor changes to an approved test procedure - Accepted | 26/09/2025 | N/A |                                  |                                                                                                                                                                   |
| Variation type IB / EMA/VR/0000284382 | This was an application for a group of variations. B.II.g.5 Implementation of changes foreseen in an approved change management protocol - B.II.g.5.c Implementation of a change for a biological/immunological medicinal product - Accepted                                                                                                                                                                                                                                                                                                              | 30/07/2025 |     | SmPC, Annex II, Labelling and PL |                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                                       | B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.2 Change outside the range of the currently approved pack sizes - Accepted                                                                                                                                                                                                                                                        |            |     |                   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IB /                   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted                                                       | 22/05/2025 | N/A | EMA/VR/0000262181 |
| Variation type II / EMA/VR/0000246665 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.c The change requires assessment of the comparability of a biological/immunological active substance - Accepted | 08/05/2025 | N/A |                   |

<div style=\"page-break-after: always\"></div>

| Variation type II / EMA/VR/0000246981   | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.d Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological reagent for a biological active substance - Accepted   | 10/04/2025   | N/A   |
|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|